STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...
Staar Surgical (Nasdaq:STAA) announced that it received FDA approval for an expanded age indication for its Evo lenses.
STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved an expanded age indication for Staar Surgical Company’s STAA ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release ...
Preliminary net sales of $94.7 million, up 6.9% compared to $88.6 million in the prior year period. Preliminary net sales included $25.9 million related to the previously disclosed December 2024 ICL ...
On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO ...
Geneva, Switzerland-based eye care company Alcon has agreed to buy Staar Surgical for $28 a share in cash. This represents a total equity value of about $1.5 billion. Lake Forest, CA-based Staar ...
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, ...
LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today ...
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results